Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced a conference call and live webcast on March 30, 2023, at 8:30 a.m. ET, to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The event will offer a corporate update and can be accessed through the investor relations section of Avadel's website. The company’s lead drug candidate, LUMRYZ™, is currently under investigation for treating narcolepsy symptoms. A replay of the event will be available for 90 days post-call.

Positive

• Upcoming conference call to discuss financial results and corporate updates.
• Lead drug candidate LUMRYZ™ targets a significant market need for narcolepsy treatment.

Negative

• None.

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

When is the Avadel Pharmaceuticals conference call scheduled?

The conference call is scheduled for March 30, 2023, at 8:30 a.m. ET.

What financial results will Avadel Pharmaceuticals discuss?

Avadel Pharmaceuticals will discuss its financial results for the fourth quarter and full year ended December 31, 2022.

Where can I access the Avadel Pharmaceuticals conference call?

The conference call can be accessed via the investor relations section of Avadel's website.

What is LUMRYZ™ by Avadel Pharmaceuticals?

LUMRYZ™ is an investigational formulation of sodium oxybate aimed at treating symptoms of narcolepsy.